oxybutynin has been researched along with Hyperidrosis in 57 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate efficacy of 20% oxybutynin hydrochloride lotion (20% OL) in reducing palmar sweat volume in patients with primary palmar hyperhidrosis (PPHH)." | 9.69 | A novel lotion formulation of 20% oxybutynin hydrochloride for the treatment of primary palmar hyperhidrosis: A randomized, placebo-controlled, double-blind, phase III study. ( Fujimoto, T; Hirayama, Y; Inakura, H; Okawa, K; Terahara, T; Yokozeki, H, 2023) |
| "Oxybutynin gel and nanoemulgel offer equal safety and similar efficacy in reducing the disease severity and increasing the quality of life of patients with palmar hyperhidrosis." | 9.69 | Oxybutynin gel versus nanoemulgel for treating primary palmar hyperhidrosis: A pilot double-blind randomized controlled trial. ( Ahramiyanpour, N; Alipour, S; Hosseini, SA; Rastaghi, F; Saki, N; Shakouri, N, 2023) |
| "The long-term safety and efficacy of 52-week application of oxybutynin hydrochloride 20% lotion (20% OL) for the treatment of primary palmar hyperhidrosis (PPHH) in Japanese patients aged ≥12 years were evaluated in an open-label extension (OLE) of a 4-week, randomized, double-blind (DB) study." | 9.69 | Long-term evaluation of the safety and efficacy of a novel 20% oxybutynin hydrochloride lotion for primary palmar hyperhidrosis: An open-label extension study. ( Fujimoto, T; Hirayama, Y; Inakura, H; Okawa, K; Terahara, T; Yokozeki, H, 2023) |
| "Our study suggests that using oxybutynin as a treatment for hyperhidrosis is significant and needs to be highlighted for clinicians." | 9.41 | Safety and efficacy of oxybutynin in patients with hyperhidrosis: systematic review and meta-analysis of randomized controlled trials. ( Abdelwahab, OA; Amro, S; Badawy, MM; El-Samahy, M; Fayad, T; Mouffokes, A, 2023) |
| "Oral oxybutynin for treating hyperhidrosis is effective and safe." | 9.24 | Initial study of transdermal oxybutynin for treating hyperhidrosis. ( de Troya-Martín, M; Del Boz, J; García-Montero, P; Millán-Cayetano, JF; Nieto-Guindo, M; Toledo-Pastrana, T, 2017) |
| "To evaluate the effectiveness and tolerance of low-dose oxybutynin for hyperhidrosis." | 9.20 | Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial. ( Abasq-Thomas, C; Brenaut, E; Chassain-Le Lay, M; Dupré-Goetghebeur, D; Gouedard, C; Greco, M; Jouan, N; Le Gal, G; Le Ru, Y; Menard-Andivot, N; Misery, L; Penven, K; Pillette-Delarue, M; Roguedas-Contios, AM; Sassolas, B; Schollhammer, M; Zagnoli, A, 2015) |
| "Oxybutynin was effective in the treatment of persistent plantar hyperhidrosis, resulting in a better quality of life in women who had undergone thoracoscopic sympathectomy." | 9.19 | Randomized trial - oxybutynin for treatment of persistent plantar hyperhidrosis in women after sympathectomy. ( Costa, Ada S; Filho Aurelio Marchetti, M; Filho Castelo, A; Leão, LE; Perfeito, JA; Rymkiewicz, E; Succi, JE, 2014) |
| "Among patients with good initial responses to oxybutynin, more than 90 % experienced moderate or great improvement in their palmar sweating, as well as in their hyperhidrosis in other sites, after 6 months." | 9.19 | Long-term results of oxybutynin treatment for palmar hyperhidrosis. ( de Campos, JR; de Paula, RP; Kauffman, P; Krutman, M; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2014) |
| "This study evaluated the effectiveness and patient satisfaction of oral oxybutynin at low doses (5 mg twice daily) compared with placebo for treating palmar hyperhidrosis." | 9.16 | A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis. ( de Campos, JR; Kauffman, P; Puech-Leão, P; Wolosker, N, 2012) |
| "The use of oxybutynin is an alternative as the first step in the treatment of palmar hyperhidrosis, given that it presents good results and improves QOL." | 9.15 | An alternative to treat palmar hyperhidrosis: use of oxybutynin. ( de Campos, JR; Jatene, FB; Kauffman, P; Neves, S; Puech-Leão, P; Wolosker, N; Yazbek, G, 2011) |
| "This study included a large number of patients followed for a long period and demonstrated the good effectiveness of treatment with oxybutynin for hyperhidrosis in the main sites of sweating." | 7.96 | Long-term results of the treatment of primary hyperhidrosis with oxybutynin: follow-up of 1,658 cases. ( da Silva, MFA; de Campos, JRM; Faustino, CB; Kauffman, P; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2020) |
| "Oxybutynin chloride and botulinum toxin type A (BTX-A) have demonstrated to be effective treatments for primary palmar hyperhidrosis (PPH); however, both of them are not completely free from local and/or generalized side effects." | 7.96 | Combined treatment of palmar hyperhidrosis with botulinum toxin type A and oxybutynin chloride: Results of a clinical, multicenter, prospective study. ( Bobyr, I; Campanati, A; Consales, V; Diotallevi, F; Gregoriou, S; Kontochristopoulos, G; Martina, E; Offidani, A; Platsidaki, E; Rizzetto, G, 2020) |
| "Oral oxybutynin (OOx) is an effective and safe treatment for the treatment of hyperhidrosis (HH)." | 7.96 | Tolerance of oral oxybutynin in the treatment of hyperhidrosis. ( de Troya Martin, M; Del Boz Gonzalez, J; Millán-Cayetano, JF; Rodríguez Barón, D, 2020) |
| "Oral anticholinergics such as oxybutynin (OOx) and glycopyrrolate (OGly) are frequently used in the management of hyperhidrosis." | 7.96 | Survival study of treatment adherence by patients given oral glycopyrrolate for hyperhidrosis following treatment failure with oral oxybutynin. ( Del Boz, J; García-Souto, F; Polo-Padillo, J; Rivas-Ruiz, F, 2020) |
| "There was a significant improvement in quality of life and a reduction in sweating and malodor after six weeks of treatment with topical agents and oxybutynin in patients with both hyperhidrosis and osmidrosis." | 7.88 | Combination of topical agents and oxybutynin as a therapeutic modality for patients with both osmidrosis and hyperhidrosis. ( Campos, JRM; Fukuda, JM; Kauffman, P; Mendes, CA; Pinheiro, LL; Teivelis, MP; Varella, AYM; Wolosker, N, 2018) |
| "Most studies of oral oxybutynin (OOx) for the treatment of hyperhidrosis (HH) have assumed a stable treatment protocol, without taking into account adverse effects (AE) or seasonal variations in temperature." | 7.88 | Adjusting oral oxybutynin medication for hyperhidrosis to reflect seasonal temperature variations. ( de Troya-Martín, M; Del Boz, J; García-Harana, C; García-Montero, P; Millán-Cayetano, JF; Rivas-Ruiz, F, 2018) |
| "Oxybutynin 3% gel reduced hyperhidrosis severity and improved health-related quality of life in this small pilot study." | 7.88 | Oxybutynin 3% gel for the treatment of primary focal hyperhidrosis in adolescents and young adults. ( Abbott, J; Bruckner, AL; Gralla, J; Nguyen, NV, 2018) |
| "Oral oxybutynin may be an effective and safe option for the long-term treatment of hyperhidrosis." | 7.85 | Oral oxybutynin for the treatment of hyperhidrosis: outcomes after one-year follow-up. ( Blázquez-Sánchez, N; de Troya-Martín, M; Del Boz, J; Hernández Ibáñez, C; Millán-Cayetano, JF; Rivas-Ruiz, F, 2017) |
| "This prospective study of 25 patients treated twice weekly with transdermal oxybutynin patches over 10 weeks assessed treatment response on 2 subjective scales: the Hyperhidrosis Disease Severity Scale (HDSS) and a visual analog scale (VAS) for sweating." | 7.83 | Preliminary Experience with Transdermal Oxybutynin Patches for Hyperhidrosis. ( Bergón-Sendín, M; Pulido-Pérez, A; Sáez-Martín, LC; Suárez-Fernández, R, 2016) |
| "Oral anticholinergic drugs, such as oxybutynin, are often used in the treatment of hyperhidrosis, but few studies have focused on dosing strategies for children." | 7.83 | Individualized Dosing of Oral Oxybutynin for the Treatment of Primary Focal Hyperhidrosis in Children and Teenagers. ( Blázquez-Sánchez, N; de Troya, M; Del Boz, J; Millán-Cayetano, JF, 2016) |
| "From September 2007 to September 2013, 85 consecutive patients were enrolled in our institutional protocol for the "pharmacological-first" treatment of primary plantar hyperhidrosis with oxybutynin." | 7.81 | Long-term results of the use of oxybutynin for the treatment of plantar hyperhidrosis. ( de Campos, JR; de Paula, RP; Kauffman, P; Krutman, M; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2015) |
| " Oxybutynin is effective for treating bothersome hyperhidrosis, even at atypical locations and most patients cope well with the side effects." | 7.80 | Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin. ( Campos, JR; Kauffman, P; Krutman, M; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2014) |
| "Improvements in hyperhidrosis after oxybutynin treatment were similar in both groups, suggesting that QOL before treatment is not a predictive factor for clinical outcomes, contrasting with surgical results that disclose significantly better results in patients with initially poorer QOL analysis." | 7.80 | Quality of life before hyperhidrosis treatment as a predictive factor for oxybutynin treatment outcomes in palmar and axillary hyperhidrosis. ( Campbell, TP; de Campos, JR; Kauffman, P; Krutman, M; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2014) |
| "From January 2007 to December 2010, 35 consecutive patients with plantar hyperhidrosis were treated with oxybutynin." | 7.79 | Use of oxybutynin for treating plantar hyperhidrosis. ( de Campos, JR; Kauffman, P; Neves, S; Puech-Leao, P; Wolosker, N; Yazbek, G, 2013) |
| "Oxybutynin is being increasingly being prescribed in the treatment of hyperhidrosis but currently, there is no precise dosage for this treatment." | 7.78 | [Use of oral oxybutynin at 7.5 mg per day in primary hyperhidrosis]. ( Aubin, F; Elkhyat, A; Humbert, RP; Messikh, R; Try, C, 2012) |
| "To evaluate the effectiveness and patient satisfaction with the use of oxybutynin for treating axillary hyperhidrosis in a large series of patients." | 7.77 | The use of oxybutynin for treating axillary hyperhidrosis. ( BiscegliJatene, F; de Campos, JR; Kauffman, P; Munia, MA; Neves, S; Puech-Leão, P; Wolosker, N, 2011) |
| "All patients treated with oxybutynin between February 2008 and October 2010 for troublesome generalized hyperhidrosis were recruited after ruling out underlying disease." | 7.77 | [Therapeutic value of moderate-dose oxybutynin in extensive hyperhidrosis]. ( Bara, C; Célérier, P; Fenot, M; Maillard, H, 2011) |
| "Hyperhidrosis may affect nearly 3% of the population, and thoracic/lumbar sympathectomy has been highly effective." | 6.79 | Compensatory hyperhidrosis: results of pharmacologic treatment with oxybutynin. ( Kauffman, P; Krutman, M; Milanez de Campos, JR; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2014) |
| "Hyperhidrosis is a disorder of excessive sweating severely impacting on patient's quality of life (Qol)." | 6.72 | Real-life experience with oral oxybutynin long-term continuous therapy in severe hyperhidrosis and systematic review of the literature. ( Argenziano, G; Babino, G; Briatico, G; Caccavale, S; D'Ambra, I; Fulgione, E; Giorgio, CM; Longo, C; Pampena, R, 2021) |
| "To evaluate efficacy of 20% oxybutynin hydrochloride lotion (20% OL) in reducing palmar sweat volume in patients with primary palmar hyperhidrosis (PPHH)." | 5.69 | A novel lotion formulation of 20% oxybutynin hydrochloride for the treatment of primary palmar hyperhidrosis: A randomized, placebo-controlled, double-blind, phase III study. ( Fujimoto, T; Hirayama, Y; Inakura, H; Okawa, K; Terahara, T; Yokozeki, H, 2023) |
| "Oxybutynin gel and nanoemulgel offer equal safety and similar efficacy in reducing the disease severity and increasing the quality of life of patients with palmar hyperhidrosis." | 5.69 | Oxybutynin gel versus nanoemulgel for treating primary palmar hyperhidrosis: A pilot double-blind randomized controlled trial. ( Ahramiyanpour, N; Alipour, S; Hosseini, SA; Rastaghi, F; Saki, N; Shakouri, N, 2023) |
| "The long-term safety and efficacy of 52-week application of oxybutynin hydrochloride 20% lotion (20% OL) for the treatment of primary palmar hyperhidrosis (PPHH) in Japanese patients aged ≥12 years were evaluated in an open-label extension (OLE) of a 4-week, randomized, double-blind (DB) study." | 5.69 | Long-term evaluation of the safety and efficacy of a novel 20% oxybutynin hydrochloride lotion for primary palmar hyperhidrosis: An open-label extension study. ( Fujimoto, T; Hirayama, Y; Inakura, H; Okawa, K; Terahara, T; Yokozeki, H, 2023) |
| "Hyperhidrosis is a condition of excessive sweating beyond physiological parameters that can seriously impair quality of life." | 5.56 | Oxybutynin in primary hyperhidrosis: A long-term real-life study. ( Almeida, ART; Ferrari, F; Restrepo, MVS; Rocha, VB, 2020) |
| " It also demonstrates a rare drug adverse effect with successful treatment." | 5.43 | Glycopyrrolate-induced craniofacial compensatory hyperhidrosis successfully treated with oxybutynin: report of a novel adverse effect and subsequent successful treatment. ( Fischer, R; Liu, D; Prouty, ME, 2016) |
| "Our study suggests that using oxybutynin as a treatment for hyperhidrosis is significant and needs to be highlighted for clinicians." | 5.41 | Safety and efficacy of oxybutynin in patients with hyperhidrosis: systematic review and meta-analysis of randomized controlled trials. ( Abdelwahab, OA; Amro, S; Badawy, MM; El-Samahy, M; Fayad, T; Mouffokes, A, 2023) |
| "Oxybutynin was a well-tolerated, effective, and safe method for treating postmenopausal sweating." | 5.36 | Treatment of generalized hyperhidrosis with oxybutynin in post-menopausal patients. ( Kil, HK; Kim, WO; Yoo, JH; Yoon, KB, 2010) |
| "Oral oxybutynin for treating hyperhidrosis is effective and safe." | 5.24 | Initial study of transdermal oxybutynin for treating hyperhidrosis. ( de Troya-Martín, M; Del Boz, J; García-Montero, P; Millán-Cayetano, JF; Nieto-Guindo, M; Toledo-Pastrana, T, 2017) |
| "To evaluate the effectiveness and tolerance of low-dose oxybutynin for hyperhidrosis." | 5.20 | Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial. ( Abasq-Thomas, C; Brenaut, E; Chassain-Le Lay, M; Dupré-Goetghebeur, D; Gouedard, C; Greco, M; Jouan, N; Le Gal, G; Le Ru, Y; Menard-Andivot, N; Misery, L; Penven, K; Pillette-Delarue, M; Roguedas-Contios, AM; Sassolas, B; Schollhammer, M; Zagnoli, A, 2015) |
| "Oxybutynin was effective in the treatment of persistent plantar hyperhidrosis, resulting in a better quality of life in women who had undergone thoracoscopic sympathectomy." | 5.19 | Randomized trial - oxybutynin for treatment of persistent plantar hyperhidrosis in women after sympathectomy. ( Costa, Ada S; Filho Aurelio Marchetti, M; Filho Castelo, A; Leão, LE; Perfeito, JA; Rymkiewicz, E; Succi, JE, 2014) |
| "Among patients with good initial responses to oxybutynin, more than 90 % experienced moderate or great improvement in their palmar sweating, as well as in their hyperhidrosis in other sites, after 6 months." | 5.19 | Long-term results of oxybutynin treatment for palmar hyperhidrosis. ( de Campos, JR; de Paula, RP; Kauffman, P; Krutman, M; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2014) |
| "This study evaluated the effectiveness and patient satisfaction of oral oxybutynin at low doses (5 mg twice daily) compared with placebo for treating palmar hyperhidrosis." | 5.16 | A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis. ( de Campos, JR; Kauffman, P; Puech-Leão, P; Wolosker, N, 2012) |
| "The use of oxybutynin is an alternative as the first step in the treatment of palmar hyperhidrosis, given that it presents good results and improves QOL." | 5.15 | An alternative to treat palmar hyperhidrosis: use of oxybutynin. ( de Campos, JR; Jatene, FB; Kauffman, P; Neves, S; Puech-Leão, P; Wolosker, N; Yazbek, G, 2011) |
| "Oxybutynin chloride and botulinum toxin type A (BTX-A) have demonstrated to be effective treatments for primary palmar hyperhidrosis (PPH); however, both of them are not completely free from local and/or generalized side effects." | 3.96 | Combined treatment of palmar hyperhidrosis with botulinum toxin type A and oxybutynin chloride: Results of a clinical, multicenter, prospective study. ( Bobyr, I; Campanati, A; Consales, V; Diotallevi, F; Gregoriou, S; Kontochristopoulos, G; Martina, E; Offidani, A; Platsidaki, E; Rizzetto, G, 2020) |
| "Oral anticholinergics such as oxybutynin (OOx) and glycopyrrolate (OGly) are frequently used in the management of hyperhidrosis." | 3.96 | Survival study of treatment adherence by patients given oral glycopyrrolate for hyperhidrosis following treatment failure with oral oxybutynin. ( Del Boz, J; García-Souto, F; Polo-Padillo, J; Rivas-Ruiz, F, 2020) |
| "Oral oxybutynin (OOx) is an effective and safe treatment for the treatment of hyperhidrosis (HH)." | 3.96 | Tolerance of oral oxybutynin in the treatment of hyperhidrosis. ( de Troya Martin, M; Del Boz Gonzalez, J; Millán-Cayetano, JF; Rodríguez Barón, D, 2020) |
| "This study included a large number of patients followed for a long period and demonstrated the good effectiveness of treatment with oxybutynin for hyperhidrosis in the main sites of sweating." | 3.96 | Long-term results of the treatment of primary hyperhidrosis with oxybutynin: follow-up of 1,658 cases. ( da Silva, MFA; de Campos, JRM; Faustino, CB; Kauffman, P; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2020) |
| "This study was conducted to identify the variables associated with adherence to treatment by hyperhidrosis patients treated with oral oxybutynin." | 3.88 | Survival study of treatment adherence by patients given oral oxibutynin for hyperhidrosis. ( de Troya-Martín, M; Del Boz, J; García-Harana, C; García-Montero, P; Millán-Cayetano, JF; Rivas Ruiz, F, 2018) |
| "Most studies of oral oxybutynin (OOx) for the treatment of hyperhidrosis (HH) have assumed a stable treatment protocol, without taking into account adverse effects (AE) or seasonal variations in temperature." | 3.88 | Adjusting oral oxybutynin medication for hyperhidrosis to reflect seasonal temperature variations. ( de Troya-Martín, M; Del Boz, J; García-Harana, C; García-Montero, P; Millán-Cayetano, JF; Rivas-Ruiz, F, 2018) |
| "There was a significant improvement in quality of life and a reduction in sweating and malodor after six weeks of treatment with topical agents and oxybutynin in patients with both hyperhidrosis and osmidrosis." | 3.88 | Combination of topical agents and oxybutynin as a therapeutic modality for patients with both osmidrosis and hyperhidrosis. ( Campos, JRM; Fukuda, JM; Kauffman, P; Mendes, CA; Pinheiro, LL; Teivelis, MP; Varella, AYM; Wolosker, N, 2018) |
| "Oxybutynin 3% gel reduced hyperhidrosis severity and improved health-related quality of life in this small pilot study." | 3.88 | Oxybutynin 3% gel for the treatment of primary focal hyperhidrosis in adolescents and young adults. ( Abbott, J; Bruckner, AL; Gralla, J; Nguyen, NV, 2018) |
| "VATS showed good results in patients with palmar or axillary hyperhidrosis regarding surgical response and improvement on quality of life even when the previous oxybutynin chloride treatment failed." | 3.85 | Videothoracoscopic Sympathectomy Results after Oxybutynin Chloride Treatment Failure. ( de Campos, JRM; Kauffman, P; Lembrança, L; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2017) |
| "Oral oxybutynin may be an effective and safe option for the long-term treatment of hyperhidrosis." | 3.85 | Oral oxybutynin for the treatment of hyperhidrosis: outcomes after one-year follow-up. ( Blázquez-Sánchez, N; de Troya-Martín, M; Del Boz, J; Hernández Ibáñez, C; Millán-Cayetano, JF; Rivas-Ruiz, F, 2017) |
| "This prospective study of 25 patients treated twice weekly with transdermal oxybutynin patches over 10 weeks assessed treatment response on 2 subjective scales: the Hyperhidrosis Disease Severity Scale (HDSS) and a visual analog scale (VAS) for sweating." | 3.83 | Preliminary Experience with Transdermal Oxybutynin Patches for Hyperhidrosis. ( Bergón-Sendín, M; Pulido-Pérez, A; Sáez-Martín, LC; Suárez-Fernández, R, 2016) |
| "Oral anticholinergic drugs, such as oxybutynin, are often used in the treatment of hyperhidrosis, but few studies have focused on dosing strategies for children." | 3.83 | Individualized Dosing of Oral Oxybutynin for the Treatment of Primary Focal Hyperhidrosis in Children and Teenagers. ( Blázquez-Sánchez, N; de Troya, M; Del Boz, J; Millán-Cayetano, JF, 2016) |
| "From September 2007 to September 2013, 85 consecutive patients were enrolled in our institutional protocol for the "pharmacological-first" treatment of primary plantar hyperhidrosis with oxybutynin." | 3.81 | Long-term results of the use of oxybutynin for the treatment of plantar hyperhidrosis. ( de Campos, JR; de Paula, RP; Kauffman, P; Krutman, M; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2015) |
| " Oxybutynin is effective for treating bothersome hyperhidrosis, even at atypical locations and most patients cope well with the side effects." | 3.80 | Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin. ( Campos, JR; Kauffman, P; Krutman, M; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2014) |
| "Improvements in hyperhidrosis after oxybutynin treatment were similar in both groups, suggesting that QOL before treatment is not a predictive factor for clinical outcomes, contrasting with surgical results that disclose significantly better results in patients with initially poorer QOL analysis." | 3.80 | Quality of life before hyperhidrosis treatment as a predictive factor for oxybutynin treatment outcomes in palmar and axillary hyperhidrosis. ( Campbell, TP; de Campos, JR; Kauffman, P; Krutman, M; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2014) |
| "From January 2007 to December 2010, 35 consecutive patients with plantar hyperhidrosis were treated with oxybutynin." | 3.79 | Use of oxybutynin for treating plantar hyperhidrosis. ( de Campos, JR; Kauffman, P; Neves, S; Puech-Leao, P; Wolosker, N; Yazbek, G, 2013) |
| "Oxybutynin is being increasingly being prescribed in the treatment of hyperhidrosis but currently, there is no precise dosage for this treatment." | 3.78 | [Use of oral oxybutynin at 7.5 mg per day in primary hyperhidrosis]. ( Aubin, F; Elkhyat, A; Humbert, RP; Messikh, R; Try, C, 2012) |
| "All patients treated with oxybutynin between February 2008 and October 2010 for troublesome generalized hyperhidrosis were recruited after ruling out underlying disease." | 3.77 | [Therapeutic value of moderate-dose oxybutynin in extensive hyperhidrosis]. ( Bara, C; Célérier, P; Fenot, M; Maillard, H, 2011) |
| "To evaluate the effectiveness and patient satisfaction with the use of oxybutynin for treating axillary hyperhidrosis in a large series of patients." | 3.77 | The use of oxybutynin for treating axillary hyperhidrosis. ( BiscegliJatene, F; de Campos, JR; Kauffman, P; Munia, MA; Neves, S; Puech-Leão, P; Wolosker, N, 2011) |
| "Hyperhidrosis may affect nearly 3% of the population, and thoracic/lumbar sympathectomy has been highly effective." | 2.79 | Compensatory hyperhidrosis: results of pharmacologic treatment with oxybutynin. ( Kauffman, P; Krutman, M; Milanez de Campos, JR; Puech-Leão, P; Teivelis, MP; Wolosker, N, 2014) |
| "Hyperhidrosis is a disorder of excessive sweating severely impacting on patient's quality of life (Qol)." | 2.72 | Real-life experience with oral oxybutynin long-term continuous therapy in severe hyperhidrosis and systematic review of the literature. ( Argenziano, G; Babino, G; Briatico, G; Caccavale, S; D'Ambra, I; Fulgione, E; Giorgio, CM; Longo, C; Pampena, R, 2021) |
| "Hyperhidrosis is a condition of excessive sweating beyond physiological parameters that can seriously impair quality of life." | 1.56 | Oxybutynin in primary hyperhidrosis: A long-term real-life study. ( Almeida, ART; Ferrari, F; Restrepo, MVS; Rocha, VB, 2020) |
| " It also demonstrates a rare drug adverse effect with successful treatment." | 1.43 | Glycopyrrolate-induced craniofacial compensatory hyperhidrosis successfully treated with oxybutynin: report of a novel adverse effect and subsequent successful treatment. ( Fischer, R; Liu, D; Prouty, ME, 2016) |
| "Oxybutynin was a well-tolerated, effective, and safe method for treating postmenopausal sweating." | 1.36 | Treatment of generalized hyperhidrosis with oxybutynin in post-menopausal patients. ( Kil, HK; Kim, WO; Yoo, JH; Yoon, KB, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.75) | 18.7374 |
| 1990's | 1 (1.75) | 18.2507 |
| 2000's | 7 (12.28) | 29.6817 |
| 2010's | 36 (63.16) | 24.3611 |
| 2020's | 12 (21.05) | 2.80 |
| Authors | Studies |
|---|---|
| El-Samahy, M | 1 |
| Mouffokes, A | 1 |
| Badawy, MM | 1 |
| Amro, S | 1 |
| Fayad, T | 1 |
| Abdelwahab, OA | 1 |
| Fujimoto, T | 2 |
| Terahara, T | 2 |
| Okawa, K | 2 |
| Inakura, H | 2 |
| Hirayama, Y | 2 |
| Yokozeki, H | 2 |
| Saki, N | 1 |
| Shakouri, N | 1 |
| Rastaghi, F | 1 |
| Hosseini, SA | 1 |
| Alipour, S | 1 |
| Ahramiyanpour, N | 1 |
| Wolosker, N | 14 |
| Kauffman, P | 14 |
| de Campos, JRM | 2 |
| Faustino, CB | 1 |
| da Silva, MFA | 1 |
| Teivelis, MP | 10 |
| Puech-Leão, P | 13 |
| Campanati, A | 2 |
| Gregoriou, S | 2 |
| Consales, V | 1 |
| Rizzetto, G | 1 |
| Bobyr, I | 1 |
| Diotallevi, F | 1 |
| Martina, E | 1 |
| Kontochristopoulos, G | 2 |
| Platsidaki, E | 2 |
| Offidani, A | 1 |
| Del Boz Gonzalez, J | 1 |
| Rodríguez Barón, D | 1 |
| Millán-Cayetano, JF | 7 |
| de Troya Martin, M | 1 |
| Del Boz, J | 8 |
| García-Souto, F | 2 |
| Rivas-Ruiz, F | 4 |
| Polo-Padillo, J | 2 |
| Almeida, ART | 1 |
| Ferrari, F | 1 |
| Restrepo, MVS | 1 |
| Rocha, VB | 1 |
| Colmenero-Sendra, M | 1 |
| Briatico, G | 1 |
| Pampena, R | 1 |
| Fulgione, E | 1 |
| Babino, G | 1 |
| Giorgio, CM | 1 |
| D'Ambra, I | 1 |
| Caccavale, S | 1 |
| Longo, C | 1 |
| Argenziano, G | 1 |
| Markantoni, V | 1 |
| Agiasofitou, E | 1 |
| Kouris, A | 1 |
| Offidani, AM | 1 |
| Rigopoulos, D | 1 |
| Prouty, ME | 1 |
| Fischer, R | 1 |
| Liu, D | 1 |
| Lembrança, L | 1 |
| Jarrett, JB | 1 |
| Moss, D | 1 |
| Artzi, O | 1 |
| Loizides, C | 1 |
| Zur, E | 1 |
| Sprecher, E | 1 |
| García-Montero, P | 3 |
| García-Harana, C | 2 |
| Rivas Ruiz, F | 1 |
| de Troya-Martín, M | 5 |
| Nguyen, NV | 1 |
| Gralla, J | 1 |
| Abbott, J | 1 |
| Bruckner, AL | 1 |
| Varella, AYM | 1 |
| Fukuda, JM | 2 |
| Pinheiro, LL | 1 |
| Mendes, CA | 1 |
| Campos, JRM | 1 |
| de Campos, JR | 8 |
| Yazbek, G | 2 |
| Neves, S | 3 |
| Krutman, M | 6 |
| Campbell, TP | 1 |
| de Paula, RP | 3 |
| Costa, Ada S | 1 |
| Leão, LE | 1 |
| Succi, JE | 1 |
| Perfeito, JA | 1 |
| Filho Castelo, A | 1 |
| Rymkiewicz, E | 1 |
| Filho Aurelio Marchetti, M | 1 |
| Milanez de Campos, JR | 1 |
| Campos, JR | 2 |
| Baumgartner, F | 1 |
| Karlsson-Groth, A | 1 |
| Rystedt, A | 1 |
| Swartling, C | 1 |
| Nicholas, R | 1 |
| Quddus, A | 1 |
| Baker, DM | 1 |
| Schollhammer, M | 2 |
| Brenaut, E | 1 |
| Menard-Andivot, N | 1 |
| Pillette-Delarue, M | 1 |
| Zagnoli, A | 1 |
| Chassain-Le Lay, M | 1 |
| Sassolas, B | 1 |
| Jouan, N | 1 |
| Le Ru, Y | 1 |
| Abasq-Thomas, C | 1 |
| Greco, M | 1 |
| Penven, K | 1 |
| Roguedas-Contios, AM | 1 |
| Dupré-Goetghebeur, D | 1 |
| Gouedard, C | 1 |
| Misery, L | 2 |
| Le Gal, G | 1 |
| Vary, JC | 1 |
| Blázquez-Sánchez, N | 2 |
| Hernández Ibáñez, C | 1 |
| de Troya, M | 1 |
| Bergón-Sendín, M | 1 |
| Pulido-Pérez, A | 1 |
| Sáez-Martín, LC | 1 |
| Suárez-Fernández, R | 1 |
| Varella, AY | 1 |
| Cucato, GG | 1 |
| Toledo-Pastrana, T | 1 |
| Nieto-Guindo, M | 1 |
| Pariser, DM | 1 |
| Krishnaraja, J | 1 |
| Tremblay, TM | 1 |
| Rubison, RM | 1 |
| Love, TW | 1 |
| McGraw, BF | 1 |
| Wozniacki, L | 1 |
| Zubilewicz, T | 1 |
| Kim, WO | 1 |
| Kil, HK | 1 |
| Yoon, KB | 1 |
| Yoo, JH | 1 |
| Grootens, KP | 1 |
| Jatene, FB | 1 |
| Revuz, J | 1 |
| Maillard, H | 1 |
| Fenot, M | 1 |
| Bara, C | 1 |
| Célérier, P | 1 |
| Munia, MA | 1 |
| BiscegliJatene, F | 1 |
| Try, C | 1 |
| Messikh, R | 1 |
| Elkhyat, A | 1 |
| Aubin, F | 1 |
| Humbert, RP | 1 |
| Shimizu, H | 1 |
| Tamada, Y | 1 |
| Shimizu, J | 1 |
| Ohshima, Y | 1 |
| Matsumoto, Y | 1 |
| Sugenoya, J | 1 |
| Tupker, RA | 2 |
| Harmsze, AM | 2 |
| Deneer, VH | 2 |
| Mijnhout, GS | 1 |
| Kloosterman, H | 1 |
| Simsek, S | 1 |
| Strack van Schijndel, RJ | 1 |
| Netelenbos, JC | 1 |
| Lefrandt, JD | 1 |
| Maurer, JM | 1 |
| Houte, Mv | 1 |
| Arroyo, HA | 1 |
| Di Blasi, M | 1 |
| Fejerman, N | 1 |
| LeWitt, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Retrospective Evaluation of Long Term Use of Oxybutynin in the Pharmacological Treatment of Primary Hyperhidrosis[NCT01956591] | 1,100 participants (Actual) | Observational | 2007-09-30 | Completed | |||
| The Use of Oxybutynin in Women After Thoracoscopic Sympathectomy and the Effect on Plantar Hyperhidrosis[NCT01328015] | Phase 2 | 32 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| A Prospective Study Assessing the Effect of Patient Characteristics on Treatment Response in Hyperhidrosis[NCT03694093] | 41 participants (Actual) | Observational | 2018-08-20 | Completed | |||
| The Use of Topical Oxybutynin 10% for Treating Primary Focal Hyperhidrosis-axillary, Palmar and Plantar.[NCT02973659] | 61 participants (Actual) | Interventional | 2015-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for oxybutynin and Hyperidrosis
| Article | Year |
|---|---|
Safety and efficacy of oxybutynin in patients with hyperhidrosis: systematic review and meta-analysis of randomized controlled trials.
Topics: Humans; Hyperhidrosis; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2023 |
Real-life experience with oral oxybutynin long-term continuous therapy in severe hyperhidrosis and systematic review of the literature.
Topics: Humans; Hyperhidrosis; Mandelic Acids; Muscarinic Antagonists; Quality of Life; Retrospective Studie | 2021 |
Treatment of Primary Craniofacial Hyperhidrosis: A Systematic Review.
Topics: Botulinum Toxins, Type A; Cholinergic Antagonists; Facial Dermatoses; Ganglionectomy; Glycopyrrolate | 2015 |
Selected Disorders of Skin Appendages--Acne, Alopecia, Hyperhidrosis.
Topics: Acetylcholine Release Inhibitors; Acne Vulgaris; Algorithms; Alopecia; Anti-Bacterial Agents; Antipe | 2015 |
Oxybutynin: dry days for patients with hyperhidrosis.
Topics: Female; Humans; Hyperhidrosis; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Sweat Glands | 2006 |
Oxybutynin: dry days for patients with hyperhidrosis.
Topics: Female; Humans; Hyperhidrosis; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Sweat Glands | 2006 |
Oxybutynin: dry days for patients with hyperhidrosis.
Topics: Female; Humans; Hyperhidrosis; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Sweat Glands | 2006 |
Oxybutynin: dry days for patients with hyperhidrosis.
Topics: Female; Humans; Hyperhidrosis; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Sweat Glands | 2006 |
16 trials available for oxybutynin and Hyperidrosis
| Article | Year |
|---|---|
A novel lotion formulation of 20% oxybutynin hydrochloride for the treatment of primary palmar hyperhidrosis: A randomized, placebo-controlled, double-blind, phase III study.
Topics: Double-Blind Method; Humans; Hyperhidrosis; Mandelic Acids; Sweat; Treatment Outcome | 2023 |
Oxybutynin gel versus nanoemulgel for treating primary palmar hyperhidrosis: A pilot double-blind randomized controlled trial.
Topics: Humans; Hyperhidrosis; Pilot Projects; Quality of Life; Treatment Outcome | 2023 |
Long-term evaluation of the safety and efficacy of a novel 20% oxybutynin hydrochloride lotion for primary palmar hyperhidrosis: An open-label extension study.
Topics: Adolescent; Double-Blind Method; Humans; Hyperhidrosis; Mandelic Acids; Treatment Outcome | 2023 |
Topical Oxybutynin 10% Gel for the Treatment of Primary Focal Hyperhidrosis: A Randomized Double-blind Placebo-controlled Split Area Study.
Topics: Administration, Topical; Adolescent; Adult; Double-Blind Method; Female; Gels; Humans; Hyperhidrosis | 2017 |
Long-term results of the use of oxybutynin for the treatment of axillary hyperhidrosis.
Topics: Adolescent; Adult; Aged; Axilla; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Adm | 2014 |
Randomized trial - oxybutynin for treatment of persistent plantar hyperhidrosis in women after sympathectomy.
Topics: Adult; Female; Humans; Hyperhidrosis; Mandelic Acids; Muscarinic Antagonists; Patient Satisfaction; | 2014 |
Compensatory hyperhidrosis: results of pharmacologic treatment with oxybutynin.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up | 2014 |
Long-term results of oxybutynin treatment for palmar hyperhidrosis.
Topics: Adolescent; Adult; Body Mass Index; Child; Child, Preschool; Female; Hand; Humans; Hyperhidrosis; Ma | 2014 |
Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Female; Humans; Hyperhidrosis; Male; Mandelic A | 2015 |
Initial study of transdermal oxybutynin for treating hyperhidrosis.
Topics: Administration, Cutaneous; Adult; Aged; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Middle | 2017 |
Randomized, Placebo- and Active-Controlled Crossover Study of the Safety and Efficacy of THVD-102, a Fixed-dose Combination of Oxybutynin and Pilocarpine, in Subjects With Primary Focal Hyperhidrosis.
Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Humans; Hyperhidros | 2017 |
An alternative to treat palmar hyperhidrosis: use of oxybutynin.
Topics: Adolescent; Adult; Epidermis; Hand; Humans; Hyperhidrosis; Mandelic Acids; Middle Aged; Parasympatho | 2011 |
A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis.
Topics: Adolescent; Adult; Brazil; Chi-Square Distribution; Drug Administration Schedule; Female; Humans; Hy | 2012 |
A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis.
Topics: Adolescent; Adult; Brazil; Chi-Square Distribution; Drug Administration Schedule; Female; Humans; Hy | 2012 |
A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis.
Topics: Adolescent; Adult; Brazil; Chi-Square Distribution; Drug Administration Schedule; Female; Humans; Hy | 2012 |
A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis.
Topics: Adolescent; Adult; Brazil; Chi-Square Distribution; Drug Administration Schedule; Female; Humans; Hy | 2012 |
Effectiveness of iontophoresis with alternating current (AC) in the treatment of patients with palmoplantar hyperhidrosis.
Topics: Adult; Cholinergic Antagonists; Female; Foot Diseases; Hand; Humans; Hyperhidrosis; Iontophoresis; M | 2003 |
Oxybutynin therapy for generalized hyperhidrosis.
Topics: Administration, Oral; Adult; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Muscarinic Antagon | 2006 |
Oxybutynin therapy for generalized hyperhidrosis.
Topics: Administration, Oral; Adult; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Muscarinic Antagon | 2006 |
Oxybutynin therapy for generalized hyperhidrosis.
Topics: Administration, Oral; Adult; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Muscarinic Antagon | 2006 |
Oxybutynin therapy for generalized hyperhidrosis.
Topics: Administration, Oral; Adult; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Muscarinic Antagon | 2006 |
Exercise-induced sweating in healthy subjects as a model to predict a drug's sweat-reducing properties in hyperhydrosis: a prospective, placebo-controlled, double-blind study.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Drug Evaluation; Exercise; Humans; Hyperhidrosis; Ma | 2008 |
36 other studies available for oxybutynin and Hyperidrosis
| Article | Year |
|---|---|
Long-term results of the treatment of primary hyperhidrosis with oxybutynin: follow-up of 1,658 cases.
Topics: Administration, Oral; Adolescent; Adult; Axilla; Drug Administration Schedule; Face; Female; Follow- | 2020 |
Combined treatment of palmar hyperhidrosis with botulinum toxin type A and oxybutynin chloride: Results of a clinical, multicenter, prospective study.
Topics: Botulinum Toxins, Type A; Humans; Hyperhidrosis; Mandelic Acids; Prospective Studies; Quality of Lif | 2020 |
Tolerance of oral oxybutynin in the treatment of hyperhidrosis.
Topics: Humans; Hyperhidrosis; Mandelic Acids; Muscarinic Antagonists; Retrospective Studies; Treatment Outc | 2020 |
Survival study of treatment adherence by patients given oral glycopyrrolate for hyperhidrosis following treatment failure with oral oxybutynin.
Topics: Adult; Female; Glycopyrrolate; Humans; Hyperhidrosis; Mandelic Acids; Muscarinic Antagonists; Prospe | 2020 |
Oxybutynin in primary hyperhidrosis: A long-term real-life study.
Topics: Adolescent; Adult; Aged; Child; Female; Humans; Hyperhidrosis; Longitudinal Studies; Male; Mandelic | 2020 |
Craniofacial hyperhidrosis: Clinical characteristics and response to treatment in a cohort of 97 patients treated with oral oxybutynin.
Topics: Axilla; Humans; Hyperhidrosis; Mandelic Acids; Prospective Studies; Treatment Outcome | 2021 |
Treatment of primary axillary hyperhidrosis with a cream formulation of oxybutynin chloride 10.
Topics: Axilla; Humans; Hyperhidrosis; Mandelic Acids; Quality of Life; Treatment Outcome | 2021 |
Glycopyrrolate-induced craniofacial compensatory hyperhidrosis successfully treated with oxybutynin: report of a novel adverse effect and subsequent successful treatment.
Topics: Adult; Deprescriptions; Female; Glycopyrrolate; Humans; Hyperhidrosis; Mandelic Acids; Muscarinic An | 2016 |
Videothoracoscopic Sympathectomy Results after Oxybutynin Chloride Treatment Failure.
Topics: Adolescent; Adult; Brazil; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Muscarinic Antagonis | 2017 |
PURLs: Oral agent offers relief from generalized hyperhidrosis
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Hyperhidrosis; Mandelic Acids; Muscarinic A | 2017 |
Survival study of treatment adherence by patients given oral oxibutynin for hyperhidrosis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Child; Child, Preschool; Female; Humans; Hyperhidrosi | 2018 |
Oxybutynin 3% gel for the treatment of primary focal hyperhidrosis in adolescents and young adults.
Topics: Administration, Topical; Adolescent; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Parasympat | 2018 |
Combination of topical agents and oxybutynin as a therapeutic modality for patients with both osmidrosis and hyperhidrosis.
Topics: Administration, Topical; Adolescent; Adult; Anti-Bacterial Agents; Antifungal Agents; Child; Child, | 2018 |
Adjusting oral oxybutynin medication for hyperhidrosis to reflect seasonal temperature variations.
Topics: Administration, Oral; Adult; Drug Dosage Calculations; Female; Humans; Hyperhidrosis; Male; Mandelic | 2018 |
Use of oxybutynin for treating plantar hyperhidrosis.
Topics: Adolescent; Adult; Aged; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Middle Aged; Muscarini | 2013 |
Quality of life before hyperhidrosis treatment as a predictive factor for oxybutynin treatment outcomes in palmar and axillary hyperhidrosis.
Topics: Adolescent; Adult; Child; Child, Preschool; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Mid | 2014 |
Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin.
Topics: Adolescent; Adult; Aged; Female; Follow-Up Studies; Humans; Hyperhidrosis; Male; Mandelic Acids; Mid | 2014 |
Invited commentary.
Topics: Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Patient Satisfaction | 2014 |
Long-term results of the use of oxybutynin for the treatment of plantar hyperhidrosis.
Topics: Adolescent; Adult; Aged; Algorithms; Child; Female; Foot Dermatoses; Humans; Hyperhidrosis; Mandelic | 2015 |
Treatment of compensatory hyperhidrosis after sympathectomy with botulinum toxin and anticholinergics.
Topics: Adult; Aged; Botulinum Toxins; Cholinergic Antagonists; Female; Humans; Hyperhidrosis; Male; Mandeli | 2015 |
Oral oxybutynin for the treatment of hyperhidrosis: outcomes after one-year follow-up.
Topics: Administration, Oral; Adolescent; Adult; Aged; Child; Child, Preschool; Female; Follow-Up Studies; H | 2017 |
Individualized Dosing of Oral Oxybutynin for the Treatment of Primary Focal Hyperhidrosis in Children and Teenagers.
Topics: Administration, Oral; Adolescent; Age Factors; Child; Dose-Response Relationship, Drug; Drug Adminis | 2016 |
Oral glycopyrrolate after the failure of oral oxybutynin in the treatment of primary hyperhidrosis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Child; Drug Administration Schedule; Female; Glycopyr | 2017 |
Preliminary Experience with Transdermal Oxybutynin Patches for Hyperhidrosis.
Topics: Administration, Cutaneous; Adolescent; Adult; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; M | 2016 |
Translation and validation of Hyperhidrosis Disease Severity Scale.
Topics: Adolescent; Adult; Brazil; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Middle Aged; Quality | 2016 |
Primary hyperhidrosis controlled with oxybutynin after unsuccessful surgical treatment.
Topics: Humans; Hyperhidrosis; Male; Mandelic Acids; Parasympatholytics; Sympathectomy; Young Adult | 2009 |
Treatment of generalized hyperhidrosis with oxybutynin in post-menopausal patients.
Topics: Female; Humans; Hyperhidrosis; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Postmenopause; P | 2010 |
Oxybutynin for antidepressant-induced hyperhidrosis.
Topics: Antidepressive Agents, Tricyclic; Clomipramine; Humans; Hyperhidrosis; Male; Mandelic Acids; Middle | 2011 |
[Retrospective studies and therapeutic research].
Topics: Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Parasympatholytics | 2011 |
[Therapeutic value of moderate-dose oxybutynin in extensive hyperhidrosis].
Topics: Adult; Drug Evaluation; Female; Follow-Up Studies; Humans; Hyperhidrosis; Male; Mandelic Acids; Midd | 2011 |
The use of oxybutynin for treating axillary hyperhidrosis.
Topics: Adolescent; Adult; Axilla; Brazil; Chi-Square Distribution; Drug Administration Schedule; Female; Hu | 2011 |
[Use of oral oxybutynin at 7.5 mg per day in primary hyperhidrosis].
Topics: Administration, Oral; Adolescent; Adult; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Middle | 2012 |
[Use of oral oxybutynin at 7.5 mg per day in primary hyperhidrosis].
Topics: Administration, Oral; Adolescent; Adult; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Middle | 2012 |
[Use of oral oxybutynin at 7.5 mg per day in primary hyperhidrosis].
Topics: Administration, Oral; Adolescent; Adult; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Middle | 2012 |
[Use of oral oxybutynin at 7.5 mg per day in primary hyperhidrosis].
Topics: Administration, Oral; Adolescent; Adult; Female; Humans; Hyperhidrosis; Male; Mandelic Acids; Middle | 2012 |
Treatment of hyperhidrosis with oxybutynin.
Topics: Adult; Humans; Hyperhidrosis; Mandelic Acids; Muscarinic Antagonists; Parasympatholytics; Urinary Bl | 2007 |
Oxybutynin for hyperhidrosis.
Topics: Adolescent; Adult; Depression; Female; Glycopyrrolate; Humans; Hyperhidrosis; Male; Mandelic Acids; | 2007 |
Episodic spontaneous hypothermia with hyperhidrosis.
Topics: Body Temperature Regulation; Cyproheptadine; Female; Humans; Hyperhidrosis; Hypothermia; Infant; Man | 1994 |
Hyperhidrosis and hypothermia responsive to oxybutynin.
Topics: Body Temperature; Humans; Hyperhidrosis; Hypothermia; Mandelic Acids; Urination Disorders | 1988 |